RT @RobotRrid: .@Cellosaurus, https://t.co/eqEFFWe62L was used by the authors of the Cancer Research paper "Targeting ribonucleotide reduct…
.@Cellosaurus, https://t.co/eqEFFWe62L was used by the authors of the Cancer Research paper "Targeting ribonucleotide reductase induces synthet…": https://t.co/MvDn73VNTe (https://t.co/WS2BVapx6V). Thank you for making your #methodsmatter. #OpenScience
🧐🎀 #Cancer #uterus: une étude chez la #souris 🐁 confirme une solution thérapeutique contre la mutation du gène PP2A, très fréquent dans le cadre du carcinome séreux utérin 🙏 https://t.co/oozwvvnGi8 https://t.co/pl2Vu49k1o
#3GYNPath @AACR Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma https://t.co/dU8TXbYbBJ
RT @pharmacocaitlin: Very excited that our research came out today in @CR_AACR! We found that uterine serous carcinomas were more susceptib…
RT @NarlaLabUMich: The Narla Lab is very excited to share Dr. Caitlin O'Connor's (@pharmacocaitlin) first postdoctoral paper, published tod…
RT @pharmacocaitlin: Very excited that our research came out today in @CR_AACR! We found that uterine serous carcinomas were more susceptib…
Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma https://t.co/aX8bULIfUl
New article: Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma https://t.co/JlK3GOqQug #uterinecancer #oncology https://t.co/Kc0EJempqE
Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma | Cancer Research @drdonsdizon https://t.co/cCxavd2qHn
RT @pharmacocaitlin: Very excited that our research came out today in @CR_AACR! We found that uterine serous carcinomas were more susceptib…
PP2A mutation is present in up to 40% of uterine serous carcinomas; ribonucleotide reductase inhibitor works in this class https://t.co/wiucgCun16
RT @pharmacocaitlin: Very excited that our research came out today in @CR_AACR! We found that uterine serous carcinomas were more susceptib…
RT @pharmacocaitlin: Very excited that our research came out today in @CR_AACR! We found that uterine serous carcinomas were more susceptib…
RT @NarlaLabUMich: The Narla Lab is very excited to share Dr. Caitlin O'Connor's (@pharmacocaitlin) first postdoctoral paper, published tod…
RT @pharmacocaitlin: Very excited that our research came out today in @CR_AACR! We found that uterine serous carcinomas were more susceptib…
The Narla Lab is very excited to share Dr. Caitlin O'Connor's (@pharmacocaitlin) first postdoctoral paper, published today in @CR_AACR ! https://t.co/rzAnF8tUho #UniversityOfMichigan #Michigan #MichiganMedicine #RogelCancerCenter #Cancer #Research #CancerR
RT @pharmacocaitlin: Very excited that our research came out today in @CR_AACR! We found that uterine serous carcinomas were more susceptib…
RT @pharmacocaitlin: Very excited that our research came out today in @CR_AACR! We found that uterine serous carcinomas were more susceptib…
RT @pharmacocaitlin: Very excited that our research came out today in @CR_AACR! We found that uterine serous carcinomas were more susceptib…
Very excited that our research came out today in @CR_AACR! We found that uterine serous carcinomas were more susceptible to treatment with RNR inhibitors and hope this will have translational impact. https://t.co/jZHpcD3xNe
Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma https://t.co/kCqxd8ldIY Proud of our collaborative research team - hopefully this work can be make an impact for patients suffering from this deadly